
1. Technology overview
Scanvio Medical AG is a Zurich-based company (The Circle 60, 8058 Zurich) that was officially incorporated on 2 May 2024. Its mission is a more timely diagnosis of endometriosis.
Scanvio Assist provides real-time AI analysis during transvaginal ultrasound. It gives live feedback that guides the gynecologist through the exam, highlights relevant pelvic structures and potential signs of endometriosis, supports disease mapping and severity estimation, and produces standardized structured reports. It is offered as a software add-on for ultrasound manufacturers. Named clinical voices include the Endometriosis Unit at University Hospital Zurich.
2. Highlighted features & specifications
- Real-time analysis: AI works live during transvaginal ultrasound.
- Exam guidance: Live feedback guides the gynecologist through the examination.
- Structure highlighting: Marks pelvic structures and potential signs of endometriosis.
- Disease mapping: Supports mapping and severity estimation.
- Structured reports: Produces standardized reports.
- OEM add-on: Available as a software add-on for ultrasound manufacturers.
3. Potential application
Gynecology departments and women's hospitals in Vietnam adding AI to transvaginal ultrasound. Ultrasound device distributors bundling the add-on. Fertility clinics screening for endometriosis.
4. Benefits
Real-time guidance helps gynecologists spot endometriosis signs during the same exam. Standardized structured reports. Delivered as a software add-on, so ultrasound vendors can integrate it into existing systems. CE Class IIa status under the MDR enables first clinical rollouts in Europe.
5. Market trends & opportunities
Endometriosis diagnosis is often delayed, and ultrasound AI that works inside the routine exam lowers the need for specialist referral. Vietnamese and Southeast Asian ultrasound distributors and women's health clinics are potential channels.
6. Other information
Incorporated 2 May 2024 (Scanvio Medical AG, Zurich). Secured USD 3.4 million financing in July 2025 and CHF 150,000 from Venture Kick Stage 3 in February 2025. Ranked #22 in Swiss Top 100 Startups 2026 and #3 in MedTech (September 2026). CE mark Class IIa under MDR announced 9 October 2026.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































